Aura Biosciences, Inc. (NASDAQ:AURA - Get Free Report) insider Janet Jill Hopkins sold 11,822 shares of the company's stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the transaction, the insider now owns 151,693 shares of the company's stock, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
Aura Biosciences Price Performance
Shares of Aura Biosciences stock opened at $9.14 on Tuesday. The stock has a market capitalization of $456.54 million, a P/E ratio of -5.28 and a beta of 0.33. Aura Biosciences, Inc. has a one year low of $6.63 and a one year high of $12.38. The business's 50 day simple moving average is $9.82 and its two-hundred day simple moving average is $8.54.
Aura Biosciences (NASDAQ:AURA - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.44) by $0.02. Sell-side analysts expect that Aura Biosciences, Inc. will post -1.69 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
I was wrong. Dead wrong.
From Porter & Company | Ad
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was.
Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Here’s the full story for you.
Several analysts recently commented on the company. JMP Securities upped their target price on Aura Biosciences from $19.00 to $23.00 and gave the company a "market outperform" rating in a report on Friday, September 13th. HC Wainwright reaffirmed a "buy" rating and issued a $22.00 target price on shares of Aura Biosciences in a research report on Thursday, November 14th. Evercore ISI raised shares of Aura Biosciences to a "strong-buy" rating in a research report on Monday, September 16th. Cowen restated a "buy" rating on shares of Aura Biosciences in a report on Friday, October 18th. Finally, Scotiabank boosted their price objective on Aura Biosciences from $20.00 to $23.00 and gave the stock a "sector outperform" rating in a research report on Friday, October 18th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $23.00.
Check Out Our Latest Analysis on Aura Biosciences
Hedge Funds Weigh In On Aura Biosciences
Several large investors have recently made changes to their positions in AURA. American Century Companies Inc. purchased a new position in Aura Biosciences in the second quarter worth about $119,000. American International Group Inc. boosted its holdings in shares of Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company's stock worth $138,000 after buying an additional 3,782 shares during the last quarter. Virtu Financial LLC purchased a new position in shares of Aura Biosciences during the 1st quarter worth $144,000. SG Americas Securities LLC bought a new stake in Aura Biosciences during the third quarter valued at about $169,000. Finally, Barclays PLC grew its stake in shares of Aura Biosciences by 256.5% during the 3rd quarter. Barclays PLC now owns 61,010 shares of the company's stock valued at $544,000 after acquiring an additional 43,897 shares during the period. 96.75% of the stock is currently owned by hedge funds and other institutional investors.
About Aura Biosciences
(
Get Free Report)
Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
